Scarica l'app Stockscreener
117.14
3.47%
-4.21
Pre-mercato:
117.48
0.34
+0.29%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Incyte Corp Borsa (INCY) Ultime notizie
Q2 Earnings Roundup: Incyte (NASDAQ:INCY) And The Rest Of The Biotechnology Segment - Yahoo Finance
INCY Maintained by Wells Fargo -- Price Target Raised to $128 - GuruFocus
Wells Fargo Adjusts Price Target on Incyte to $128 From $116, Keeps Equalweight Rating - marketscreener.com
Incyte Corporation (INCY) Stock Price, News, Quote & History - Yahoo! Finance Canada
Incyte Corp. stock outperforms competitors despite losses on the day - MarketWatch
INCY or TECH: Which Is the Better Value Stock Right Now? - Zacks Investment Research
Incyte (NASDAQ:INCY) Combines High Growth Momentum With a Breakout Setup - ChartMill
Incyte patents new VRK1 inhibitors - BioWorld News
Incyte Corp Lobbyists, 2019 - OpenSecrets
INCY Maintained by JP Morgan -- Price Target Raised to $123.00 - GuruFocus
INCY Maintained by HC Wainwright & Co. -- Price Target Raised to $152 - GuruFocus
H.C. Wainwright raises Incyte stock price target on Atebrioz approval By Investing.com - Investing.com Nigeria
A legal chief with more than 25 years in pharma and biotech joins MiniMed. - Stock Titan
Mirum Pharmaceuticals and Incyte Compete Regeneron with Abnormal Bone Formation Treatment - Yahoo Finance
Incyte takes FDA approval for Atebrioz as first oral ALK2i for fibrodysplasia ossificans progressiva - AllSci
JPMorgan Adjusts Price Target on Incyte to $123 From $120, Keeps Neutral Rating - marketscreener.com
Incyte Corporation (INCY) Stock Price Today: $123.89 - Pluang
Incyte Corp Lobbyists, 2025 - OpenSecrets
About 300 people in the U.S. have a disease that causes bone to form in soft tissues. FDA approves a treatment. - Stock Titan
Mirum Pharmaceuticals wins FDA approval for Atebrioz in FOP patients 12 and older - Mugglehead Investment Magazine
INCYTE CORP (INCY) Stock Chart - ChartMill
Mirum Pharmaceuticals and Incyte Announce U.S. FDA Approval of Atebrioz™ (zilurgisertib) for Adult and Pediatric Patients with Fibrodysplasia Ossificans Progressiva - Yahoo Finance
Incyte Stock Price Forecast. Should You Buy INCY? - StockInvest.us
FDA Approves Atebrioz for Rare Bone Disorder, Boosting Incyte Co - GuruFocus
Form 4 Incyte Corporation For: 25 September By Investing.com - Investing.com Canada
Form 4 Incyte Corporation For: 25 September - Investing.com India
Bay Area company readies for decision on drug to treat alarming 'stone man' syndrome - The Business Journals
Incyte (INCY) withheld shares from its strategy chief for taxes at a reported $126.93 per share. - Stock Titan
Incyte (INCY) Stock Could Be 34% Above Fair Value After EADV Data - Yahoo Finance
Incyte (INCY) Heads To EADV With New Skin Disease Trial Data - Yahoo Finance
Analysts Offer Insights on NA Companies: Incyte (INCY) and Coherent Corp (COHR) - theglobeandmail.com
How Is Incyte’s Stock Performance Compared to Other Biotech Stocks? - Barchart.com
Incyte Corp. stock underperforms Tuesday when compared to competitors despite daily gains - MarketWatch
Incyte Corporation (INCY) latest stock news and headlines - Yahoo Finance UK
Incyte's Colorectal Cancer Program Remains Risky, Long-Term, RBC Says - marketscreener.com
INCY Reiterated by RBC Capital -- Price Target Maintained at $10 - gurufocus.com
Incyte to present inflammation and autoimmunity data at EADV - Investing.com
Incyte Data at the European Academy of Dermatology and Venereology (EADV) Congress Underscore the Breadth of Incyte’s Inflammation and Autoimmunity Portfolio - Business Wire
INCY Looks 18.6% Overvalued on GF Value™ as of September 2026 - GuruFocus
Incyte Expands Skin Diseases Treatment Partnership in Australia - marketscreener.com
Incyte stock heads into the open after a 1.8% pullback - AD HOC NEWS
Specialised Therapeutics expands Incyte partnership to Australia - Investing.com
More than 1 million patients have used this skin cream. Partners plan to bring it to Australia. - Stock Titan
Incyte stock gains institutional backing as Bank of America boosts position - AD HOC NEWS
Specialised Therapeutics Expands Partnership with Incyte to Include Ruxolitinib Cream (Opzelura®) in Australia - Yahoo Finance
Incyte Maps Post-JAKAFI Growth With Pipeline Push and $4B Sales Target - Yahoo Finance
What Is Incyte Corporation (NASDAQ:INCY) Signaling Through Its Pipeline? - Kalkine Media
Incyte stock gains as investors eye September FDA decision and pipeline catalysts - AD HOC NEWS
Incyte (NASDAQ:INCY) Combines Minervini Trend Template Strength With High-Growth Momentum - ChartMill
MIRM, INCY Stocks In Focus — Will A September 26 FDA Ruling Reward This Week’s Gains? - Stocktwits
Incyte stock heads into the open after a 2.5% gain - AD HOC NEWS
Incyte Corp. stock underperforms Thursday when compared to competitors despite daily gains - MarketWatch
Incyte Insider Sold Shares Worth $2,797,629, According to a Recent SEC Filing - marketscreener.com
Incyte (INCY) R&D chief exercises options and sells 23,218 shares - Stock Titan
Incyte Corp. (INCY) Gains 1.85% to $123.99, Holding Near the Midpoint of Its Recent RangeLow Vol ETF - careplusvn.com
Is Incyte (INCY) Undervalued After Ontario Backed MINJUVI Access? - Yahoo Finance
Incyte: Priced For Success, With No Margin Of Safety (NASDAQ:INCY) - Seeking Alpha
1.48%
0.31%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):